Last Updated: August 3, 2026

Litigation Details for Atlas IP, LLC v. Exelon Corp. (N.D. Ill. 2015)


✉ Email this page to a colleague

« Back to Dashboard


Atlas IP, LLC v. Exelon Corp. (N.D. Ill. 2015)

Docket 1:15-cv-10746 Date Filed 2015-11-30
Court District Court, N.D. Illinois Date Terminated 2016-05-17
Cause 35:271 Patent Infringement Assigned To Milton Irving Shadur
Jury Demand Both Referred To
Patents 11,052,061
Link to Docket External link to docket
Small Molecule Drugs cited in Atlas IP, LLC v. Exelon Corp.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Atlas IP, LLC v. Exelon Corp. (N.D. Ill. 2015)

Last updated: July 5, 2026

Litigation Summary and Analysis: Atlas IP, LLC v. Exelon Corp., 1:15-cv-10746

Atlas IP, LLC sued Exelon Corp. in the District of Massachusetts in 2015 (case no. 1:15-cv-10746). The record at the case level is not provided here, so an accurate, citation-ready litigation summary (asserted patents, parties’ positions, procedural posture, claim construction, PTAB activity, settlements, and injunction status) cannot be produced from the information available.

What patents did Atlas IP assert against Exelon Corp. in 1:15-cv-10746?

No asserted-patent list, patent numbers, claims, or infringement theories are available in the provided input.

What claims (device, system, method, use) were allegedly infringed?

No complaint allegations or asserted claim numbers are available in the provided input.

Which Atlas IP patent holders or corporate affiliates were involved?

No assignment history, ownership details, or inventor/assignee alignment are available in the provided input.


What was Exelon’s response in Atlas IP, LLC v. Exelon Corp. (1:15-cv-10746)?

No answer, motion-to-dismiss grounds, invalidity contentions, or affirmative defenses are available in the provided input.

What defenses were raised (non-infringement, invalidity, unenforceability)?

No defenses are available in the provided input.

Did Exelon challenge validity via PTAB?

No PTAB petition or related estoppel information is available in the provided input.


What procedural events occurred from filing to disposition in 1:15-cv-10746?

No docket dates, rulings, hearings, or final disposition are available in the provided input.

Claim construction (Markman): when, by whom, and how did it affect scope?

No Markman schedule, claim terms, or construction outcomes are available in the provided input.

Discovery and dispositive motions: what was granted or denied?

No discovery milestones or dispositive-motion outcomes are available in the provided input.


How did the court rule on patent eligibility, infringement, and invalidity?

No substantive rulings are available in the provided input.

Did the court grant summary judgment?

No summary judgment outcomes are available in the provided input.

Were any claims held indefinite or not infringed?

No findings are available in the provided input.


Was there a settlement, consent judgment, or dismissal in Atlas IP v. Exelon?

No settlement date, settlement terms, dismissal order, or consent judgment details are available in the provided input.

If settled, what was the practical effect on injunctions and licensing?

No settlement terms are available in the provided input.


What impact does Atlas IP v. Exelon have on Exelon’s operations and IP posture?

No product tie-in, design-around, licensing roadmap, or operating constraints are provided in the input.

Did Exelon redesign, stop using accused technology, or take a license?

No operational actions are available in the provided input.

Did the case influence other litigation or licensing campaigns?

No related litigation or licensing spillover is available in the provided input.


Key Takeaways

  • A factual litigation summary for Atlas IP, LLC v. Exelon Corp., 1:15-cv-10746 cannot be generated from the provided information.
  • Actionable items like asserted patents, claim-construction results, dispositive rulings, and settlement/disposition status require docket and merits specifics that are not present.

FAQs

  1. What does “1:15-cv-10746” indicate for venue and timing?
  2. How do Atlas IP patent assertions typically map to infringement theories in similar cases?
  3. What are common defenses Exelon-style respondents raise in patent cases like this?
  4. How do settlements usually affect future enforcement by non-practicing entities like Atlas IP?
  5. Where can the docket typically be found for a district-court case like this?

References (APA)

No cited sources are available from the provided input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.